3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Phase 1
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Other solid neoplasm
1
Other hematologic neoplasm
1
Myeloid
1
Gastrointestinal
1
Dermatologic
1
CNS
1
Conditions
Carcinoma, Non-Small-Cell Lung
2
Pancreatic Neoplasms
1
Myelodysplastic Syndromes
1
Mesothelioma, Malignant
1
Melanoma
1
Leukemia, Myeloid, Acute
1
Glioblastoma
1
COVID-19
1
Interventions
Azacitidine
56
Cyclophosphamide
44
fludarabine phosphate
42
fludarabine
37
Decitabine
27
venetoclax
26
Cytarabine
25
Tacrolimus
20
Specimen Handling
18
Filgrastim
18
Busulfan
18
Melphalan
17
Whole-Body Irradiation
16
Mycophenolic Acid
16
Antilymphocyte Serum
14
Granulocyte Colony-Stimulating Factor
12
Clofarabine
12
Biopsy
12
Peripheral Blood Stem Cell Transplantation
11
Injections
11
Etoposide
11
Methotrexate
10
thymoglobulin
9
Thiotepa
9
Stem Cell Transplantation
9
Lenalidomide
9
decitabine and cedazuridine drug combination
8
aldesleukin
8
Sirolimus
8
Nivolumab
8
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1
×
Myelodysplastic Syndromes
×
bemcentinib
×
Clear all
NCT06469138
2025-01-29
8479217
BerGenBio ASA
Phase 1
Completed
6 enrolled
17 charts